Gandhi Lab

Research focus

NIH R01 · 2025

Triaging dolutegravir resistance via a point-of-care urine tenofovir assay

PROJECT SUMMARY/ ABSTRACT Tenofovir (TFV)-lamivudine-dolutegravir (TLD) has been first line HIV therapy worldwide since 2018. TLD is also used as second line therapy more recently in those with a history of prior treatment experience. However, in 2024, there is evidence of increasing rates of dolutegravir (DTG) resistance globally (4-8%), with rates up to 20% among those with virologic failure and treatment experience. Integrase strand transferase inhibitor (INSTI) resistance screening worldwide is therefore an urgent global priority, although HIV drug resistance (HIVDR) is still severely rationed in most low-and-middle-income countries due to cost. HIVDR is higher among people living with…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.